Home/Filings/4/A/0001209191-20-053346
4/A//SEC Filing

ORONSKY ARNOLD L 4/A

Accession 0001209191-20-053346

CIK 0001699382other

Filed

Oct 1, 8:00 PM ET

Accepted

Oct 2, 6:42 PM ET

Size

21.9 KB

Accession

0001209191-20-053346

Insider Transaction Report

Form 4/AAmended
Period: 2020-09-25
ORONSKY ARNOLD L
Director10% Owner
Transactions
  • Purchase

    Common Stock

    2020-09-25$18.00/sh+55,555$999,99055,555 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-09-29+1,620,1011,675,656 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-09-29+3,488,3985,164,054 total(indirect: See footnote)
  • Conversion

    Series Seed Preferred Stock

    2020-09-291,620,1010 total(indirect: See footnote)
    Common Stock (1,620,101 underlying)
  • Conversion

    Series B Preferred Stock

    2020-09-291,040,6540 total(indirect: See footnote)
    Common Stock (1,040,654 underlying)
  • Conversion

    Series C Preferred Stock

    2020-09-29265,2030 total(indirect: See footnote)
    Common Stock (265,203 underlying)
  • Conversion

    Common Stock

    2020-09-29+1,040,6546,204,708 total(indirect: See footnote)
  • Conversion

    Common Stock

    2020-09-29+265,2036,469,911 total(indirect: See footnote)
  • Conversion

    Series A Preferred Stock

    2020-09-293,488,3980 total(indirect: See footnote)
    Common Stock (3,488,398 underlying)
Footnotes (2)
  • [F1]The shares are directly held by InterWest Partners X, LP ("InterWest X"). InterWest Management Partners X, LLC ("IMP X"), as the general partner of InterWest X, may be deemed to beneficially own the shares held by InterWest X. The Reporting Person is a managing director of IMP X, and as such may be deemed to beneficially own the shares held by InterWest X. The Reporting Person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
  • [F2]The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

Issuer

PMV Pharmaceuticals, Inc.

CIK 0001699382

Entity typeother

Related Parties

1
  • filerCIK 0001207833

Filing Metadata

Form type
4/A
Filed
Oct 1, 8:00 PM ET
Accepted
Oct 2, 6:42 PM ET
Size
21.9 KB